Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totaling 360,790 shares, a growth of 183.4% from the August 31st total of 127,301 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 590,511 shares, the short-interest ratio is presently 0.6 days.

Analyst Ratings Changes

BAYRY has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Price Performance

Bayer Aktiengesellschaft stock opened at $14.32 on Friday. The company has a current ratio of 1.04, a quick ratio of 0.67 and a debt-to-equity ratio of 1.05. The company has a 50-day moving average price of $14.00 and a 200 day moving average price of $12.44. Bayer Aktiengesellschaft has a 12-month low of $7.48 and a 12-month high of $15.23. The stock has a market cap of $56.28 billion, a P/E ratio of -28.08, a PEG ratio of 2.15 and a beta of 0.56.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.06. The company had revenue of $12.53 billion for the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics.